Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: J. Joseph Melenhorst, PhD – Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland Clinic
10:45 - 11:00 CEST
CAR Therapies: Beyond T-cells and CD19 as the Target
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Sunil Acharya, PhD – The University of Texas MD Anderson Cancer Center
11:00 - 11:15 CEST
Panel Discussion With Interactivity and Audience Q&A
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
11:15 - 11:25 CEST
(1912) A Tandem CD19/ROR1 CAR-NK to Overcome Apoptotic Resistance in Chronic Lymphocytic Leukemia
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Andrew Lu, SB – Dana Farber Cancer Institute
11:25 - 11:30 CEST
(1902) Impact of Treatment With Ibrutinib or Venetoclax on CAR-T Cell Generation in Patients With Chronic Lymphocytic Leukemia. Interim Analysis of the GIMEMA CLL2020 Study
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Primary Author / Presenter: Marta Coscia, MD, PhD – Department of Medicine and Surgery, University of Insubria and Department of Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi
11:30 - 12:20 CEST
Lunch
11:30 - 12:20 CEST
Lunch
Location: ICE, Foyer 0, Level 0
12:20 - 12:50 CEST
Keynote Presentation: Measurable Residual Disease in Chronic Lymphocytic Leukemia: Technical Aspects and Clinical Significance
Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1
Speaker: Tadeusz Robak, MD, PhD – Department of Hematology, Medical University of Lodz; Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital